Rx Product News

Published Online: Monday, March 18, 2013
Follow Pharmacy_Times:

Marketed by: Cangene
Indication: Varizig (varicella zoster immune globulin [human]), a sterile freeze-dried gamma globulin (IgG) fraction of human plasma containing antibodies to varicella zoster, has been approved by the FDA. The injection is indicated to reduce the severity of varicella symptoms in high-risk individuals who have been exposed to varicella zoster, including immunocompromised children, newborns, and pregnant women. The dosage of the intramuscular injection of Varizig is based on the patient’s body weight.
Dosage Form: Powder for solution for injection in a single-use vial: 125 IU
For More Information: www.cangene.com

Marketed by: Bayer HealthCare Pharmaceuticals Inc
Indication: The FDA has approved Skyla (levonorgestrel-releasing intrauterine system), a progestin-containing intrauterine system that is placed in the uterus for the prevention of pregnancy for up to 3 years. The flexible T-shaped polyethylene intrauterine device (IUD) with steroid reservoir releases 14 mcg of levonorgestrel per day after 24 days and must be removed or replaced after 3 years. Skyla is packaged within a sterile inserter and must be inserted by a trained health care provider.
Dosage Form: Intrauterine system: 13.5 mg
For More Information: www.skyla-us.com

Marketed by: Salix Pharmaceuticals Ltd
Indication: Fulyzaq (crofelemer), a first-inclass anti-diarrheal drug for adult HIV/AIDS patients who are taking anti-retroviral therapy, has been approved by the FDA. The delayed-release tablets are indicated for the relief of non-infectious diarrhea only; infectious etiologies must be ruled out before starting treatment with the drug. The recommended dose is a single 125-mg tablet taken orally twice a day, with or without food. Fulyzaq is derived from the Croton lechleri plant, native to northwestern South America.
Dosage Form: Tablets: 125 mg
For More Information: www.salix.com

Exelon Patch
Marketed by: Novartis Pharmaceuticals
Indication: The FDA has approved Exelon Patch (rivastigmine transdermal system), an acetylcholinesterase inhibitor, in a higher 13.3- mg/day dosage strength. It is indicated for treatment of mild to moderate dementia of the Alzheimer’s type or associated with Parkinson’s disease. Exelon Patch should be applied on clean, dry, hairless, intact skin on the upper or lower back, upper arm, or chest for 24 hours. The patch should be replaced with a new patch every 24 hours.
Dosage Form: Transdermal system: 4.6, 9.5, 13.3 mg/day
For More Information: www.novartis.com

Related Articles
The FDA today approved Novartis’ secukinumab (Cosentyx), an interleukin-17A antagonist, for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
The number of individuals with Alzheimer’s disease continues to escalate.
Novartis announced that it has submitted New Drug Applications to the FDA for QVA149 and NVA237, investigational drugs for the long-term maintenance treatment of chronic obstructive pulmonary disease, following positive results from phase 3 trials of the drugs.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times